H.C. Wainwright raised the firm’s price target on Genmab to $50 from $49 and keeps a Buy rating on the shares. The firm says Darzalex’s 2023 sales were relatively in line with forecasts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GMAB:
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
- Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
- Genmab downgraded to Sell from Neutral at Citi
- Biotech Alert: Searches spiking for these stocks today
